Immatics NV Aktie - 4A3

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

3,218

Gebot

3,182

Fragen

3,254

Volumen

6.925

3,188 Tagesbereich 3,50

3,006 52-Wochen-Bereich 12,60

Marktkapitalisierung

391,148M

Handelsende

3,386

Handelsbeginn

3,448

Letzte Trade

3.188

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

9.221

Ausgegebene Aktien

121.550.169

Dividendenrendite

Kurs-Gewinn-Verhältnis

-4,42

Gewinn pro Aktie (EPS)

-0,8

Erlöse

55,14M

Nettogewinn

-96,99M

Sektor

Health & Allied Services,nec

Branche

Health & Allied Services,nec

Website

www.immatics.com

Hauptsitz

Tubingen, Deu

Gegründet

Immatics NV is listed in the Health & Allied Services sector of the Tradegate (DE) with ticker 4A3. The last closing price for Immatics NV was 3,39 €. Over the last year, Immatics NV shares have traded in a share price range of 3,006 € to 12,60 €.

Immatics NV currently has 121.550.169 shares in issue. The market capitalisation of Immatics NV is 411,57 € million. Immatics NV has a price to earnings ratio (PE ratio) of -4.42.

Immatics Announces Full Year 2024 Financial Results and Business Update

Immatics Announces Full Year 2024 Financial Results and Business Update Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine®...

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME The Company will...

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates...

Immatics Announces Pricing of $150 Million Public Offering

Immatics Announces Pricing of $150 Million Public Offering Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX...

Immatics Announces Proposed $150 Million Public Offering

Immatics Announces Proposed $150 Million Public Offering Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX...

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming...

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 Houston, Texas and...

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting...

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 Houston, Texas and Tuebingen, Germany, September...

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Immatics Announces Second Quarter 2024 Financial Results and Business Update Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.992	-23.5629453682	4.21	4.21	3.006	20630	3.56472598	DE
4	-0.962	-23.014354067	4.18	5.115	3.006	12269	4.05964225	DE
12	-2.962	-47.928802589	6.18	6.27	3.006	9221	4.53857009	DE
26	-6.842	-68.0119284294	10.06	10.289999	3.006	7409	5.74768866	DE
52	-6.412	-66.5835929387	9.63	12.6	3.006	4981	7.09627065	DE
156	-4.872	-60.2224969098	8.09	13.2	3.006	4422	8.06809289	DE
260	-7.422	-69.7556390977	10.64	13.2	3.006	3906	8.08319689	DE

4A3 - Frequently Asked Questions (FAQ)

What is the current Immatics NV share price?

The current share price of Immatics NV is 3,218 €

How many Immatics NV shares are in issue?

Immatics NV has 121.550.169 shares in issue

What is the market cap of Immatics NV?

The market capitalisation of Immatics NV is EUR 411,57M

What is the 1 year trading range for Immatics NV share price?

Immatics NV has traded in the range of 3,006 € to 12,60 € during the past year

What is the PE ratio of Immatics NV?

The price to earnings ratio of Immatics NV is -4,42

What is the cash to sales ratio of Immatics NV?

The cash to sales ratio of Immatics NV is 7,78

What is the reporting currency for Immatics NV?

Immatics NV reports financial results in EUR

What is the latest annual turnover for Immatics NV?

The latest annual turnover of Immatics NV is EUR 55,14M

What is the latest annual profit for Immatics NV?

The latest annual profit of Immatics NV is EUR -96,99M

What is the registered address of Immatics NV?

The registered address for Immatics NV is PAUL-EHRLICH-STREET 15, TUBINGEN, 72076

What is the Immatics NV website address?

The website address for Immatics NV is www.immatics.com

Which industry sector does Immatics NV operate in?

Immatics NV operates in the HEALTH & ALLIED SERVICES,NEC sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
56RNanoVibronix Inc	5,00 € (85,08%)	5,6k
K1SNKlondike Silver Corporation	0,024 € (77,78%)	89k
L7C2Windfall Geotek Inc	0,0145 € (70,59%)	80,15k
2BC0Panther Minerals Inc	0,014 € (64,71%)	180,43k
AC00Banxa Holdings Inc	0,434 € (51,75%)	84,34k
MDG1Medigene AG	0,22 € (-68,48%)	878,69k
AA3IVortex Energy Corp	0,2501 € (-42,17%)	7,97k
IAHInternational Lithium Corp	0,005 € (-41,18%)	5k
E3O1Nexoptic Technology Corp	0,006 € (-29,41%)	25,31k
ID4Recylico Battery Materials Inc	0,0218 € (-29,22%)	911
3CPXiaomi Corporation	4,345 € (1,28%)	5,84M
D7GNel ASA	0,2018 € (0,80%)	4,92M
4IPParkway Corporate Ltd	0,0058 € (-3,33%)	3,5M
LHLLenovo Group Ltd	0,8798 € (-5,40%)	2,41M
LHADeutsche Lufthansa AG	5,85 € (-0,78%)	2,06M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Immatics NV (4A3)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Immatics NV

4A3 Neueste Nachrichten

Immatics Announces Full Year 2024 Financial Results and Business Update

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Immatics Announces Pricing of $150 Million Public Offering

Immatics Announces Proposed $150 Million Public Offering

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Immatics Announces Second Quarter 2024 Financial Results and Business Update

4A3 - Frequently Asked Questions (FAQ)

Beweger

4A3 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Immatics NV (4A3) Börsenkurse

Immatics NV (4A3)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Immatics NV

4A3 Neueste Nachrichten

Immatics Announces Full Year 2024 Financial Results and Business Update

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Immatics Announces Pricing of $150 Million Public Offering

Immatics Announces Proposed $150 Million Public Offering

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Immatics Announces Second Quarter 2024 Financial Results and Business Update

4A3 - Frequently Asked Questions (FAQ)

Beweger

4A3 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen